Requirement for therapeutic intervention within the 6-month period after detection of TP53/ATM abnormalities or investigation-wt in individual patient subgroups
| Status . | Group . | Treated . | Untreated . | Percentage of treated . | P . |
|---|---|---|---|---|---|
| TP53 biallelic inactivation | A | 37 | 6 | 86 | AF, < .001; AD, < .001 |
| TP53 monoallelic inactivation | B | 16 | 6 | 72 | BF, < .001; BD, .09 |
| Deletion of ATM | C | 41 | 32 | 56 | CF, < .001; CD, .47 |
| wt unmutated IgVH | D | 50 | 42 | 54 | DE, < .001 |
| wt mutated IgVH | E | 18 | 107 | 14 | |
| wt regardless of IgVH | F | 68 | 149 | 31 |
| Status . | Group . | Treated . | Untreated . | Percentage of treated . | P . |
|---|---|---|---|---|---|
| TP53 biallelic inactivation | A | 37 | 6 | 86 | AF, < .001; AD, < .001 |
| TP53 monoallelic inactivation | B | 16 | 6 | 72 | BF, < .001; BD, .09 |
| Deletion of ATM | C | 41 | 32 | 56 | CF, < .001; CD, .47 |
| wt unmutated IgVH | D | 50 | 42 | 54 | DE, < .001 |
| wt mutated IgVH | E | 18 | 107 | 14 | |
| wt regardless of IgVH | F | 68 | 149 | 31 |
IgVH indicates immunoglobulin heavy-chain variable region; wt, wild-type; and AF, group A compared with group F, and so on.